Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-Exponential T2 Components

This study is not yet open for participant recruitment.

Verified by Alberta Cancer Board, December 2008

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00813787

Purpose

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Condition
Glioma

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

T2 characteristics of glimoa tissue versus normal [ Time Frame: Before radiotherapy treatment begins ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	20
Study Start Date:	February 2009
Estimated Study Completion Date:	March 2010
Estimated Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
A. glioma A. glioma population
B. Normal brain B. Normal brain

Detailed Description:

Existing methods of contouring tumours for raditation therapy involve manual interpretations of qualitative diagnostic images. These methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. T2 component analysis in MRI has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who agrees to take part in the study.

B. Any normal volunteer who agrees to take part in the study.

Criteria

Inclusion Criteria:

Eighteen years of age or older
Clinical subjects must have not yet begun radiation therapy
Must have signed our study-specific consent form

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00813787

Contacts

Contact: Keith Wachowicz, PhD

(780) 989-4334

keithwac@cancerboard.ab.ca

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Study Chair:

Keith Wachowicz, PhD

Alberta Cancer Board

More Information

Responsible Party:	Alberta Cancer Board, Cross Cancer Institue ( B. Gino Fallone )
Study ID Numbers:	CNS-24534
Study First Received:	December 19, 2008
Last Updated:	December 22, 2008
ClinicalTrials.gov Identifier:	NCT00813787
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

Magnetic Resonance Imaging
Glioma

Study placed in the following topic categories:

Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma

Healthy
Glioma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial

ClinicalTrials.gov processed this record on January 13, 2009